Affiliation:
1. Clinical Center of Vojvodina, Clinic of Hematology, Novi Sad + University of Novi Sad, Faculty of Medicine Novi Sad
2. University Clinical Center of Serbia, Clinic of hematology + University of Belgrade, Faculty of Medicine
Abstract
Introduction. The Myeloproliferative Neoplasms are a heterogeneous group of
clonal hematopoietic stem cell disorders characterized by increased
proliferation of the myeloid lineages in the bone marrow. A particular
clinical challenge is presented by certain situations in patients with
myeloproliferative Neoplasms, which we do not encounter daily. For this
reason, in this paper, we will emphasize the approach to overcoming
obstacles in patients with Myeloproliferative Neoplasms in specific
settings, like pregnancy. Pregnancy with Philadelphia chromosome-negative
Myeloproliferative Neoplasms has been reported to be associated with
maternal thrombosis, hemorrhage, and placental dysfunction leading to fetal
growth restriction or loss. Thrombocytosis, leucocytosis, high level of
hematocrit, activation of Platelets, leucocytes, and circulating
pro-thrombotic are connected with the pathogenesis of thrombosis in MPNs
With survival expectations similar to age-matched controls and excellent
response and worldwide access to tyrosine kinase inhibitors, family planning
is increasingly important for many patients with chronic myeloid leukemia.
All patients were managed by a multidisciplinary team of physicians with
obligatory hematological and gynecologistsobstetrician consultations.
Publisher
National Library of Serbia
Reference23 articles.
1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2017.
2. Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/ dendritic neoplasms. Leukemia. 2022;36:1703-19.
3. Griesshammer M, Sadjadian P, Wille K. Contemporary management of patients with BCR/ABL-1-negative myeloproliferative neoplasms during pregnancy. Expert Rev Hematol. 2018;11(9):697-706.
4. Gangat N, Tefferi A. Myeloproliferative neoplasms and pregnancy: overview and practice recommendations. Am J Hematol. 2021;96(3):354-66.
5. Alimam S, Bewley S, Chappell LC, Knight M, Seed P, Gray G, et al. Pregnancy outcomes in myeloproliferative neoplasms: UK prospective cohort study. Br J Haematol. 2016;175(1):31-6.